Loading
Since 2016 England's Cancer Drugs Fund has paid a confidential discounted price for cancer drugs whose benefit is plausible but unproven, collected outcome data for two or three years, then had NICE decide for good; most drugs that entered were later recommended. Other systems could use the same managed-access deal instead of a yes-or-no at launch.
Since July 2016 England's Cancer Drugs Fund has operated as a managed-access scheme: NICE identifies drugs with plausible but uncertain benefit, NHS England pays a confidential discounted price under a fixed budget with an expenditure-control mechanism, and Public Health England collects outcome data; NICE then reappraises. Most drugs that entered have since been recommended for routine use. The model gives patients early access and gives the payer leverage and evidence. Germany's AMNOG, Canada's time-limited recommendations and Medicare's coverage with evidence development are partial versions.
Shares Real-world evidence, Weak real-world evidence and registries, Regulatory divergence between regions.
Shares Real-world evidence, Weak real-world evidence and registries, Regulatory divergence between regions.
Shares Real-world evidence, Weak real-world evidence and registries, Regulatory divergence between regions.
Shares Pharmaceutical Benefits Advisory Committee, Gemeinsamer Bundesausschuss / IQWiG, National Institute for Health and Care Excellence, Real-world evidence.
Shares Real-world evidence, Weak real-world evidence and registries, Prices and value.
Shares National Institute for Health and Care Excellence, Real-world evidence, Weak real-world evidence and registries, Prices and value.
Shares Real-world evidence, Weak real-world evidence and registries, Regulatory divergence between regions.
Shares Gemeinsamer Bundesausschuss / IQWiG, National Institute for Health and Care Excellence, Regulatory divergence between regions, Prices and value.